Latest Idiopathic thrombocytopenic purpura Stories
Readers are referred to the cautionary notes regarding Forward-looking information at the end of this release Listed TSX, Symbol: CNJ TORONTO and WINNIPEG, April 20 /PRNewswire-FirstCall/ - Cangene Corporation today reports that it has signed a new agreement with Baxter Healthcare Corporation under which Cangene assumes the commercialization rights to WinRho(R) SDF (Rho(D) Immune Globulin Intravenous (Human)) for the U.S.
KING OF PRUSSIA, Pa., April 19 /PRNewswire/ -- CSL Behring announced today that the U.S.
RESEARCH TRIANGLE PARK, N.C., April 12 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics, Inc., today announced results of a new survey showing that GamunexÂ® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference.
WOODCLIFF LAKE, N.J., Jan. 6 /PRNewswire/ -- Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces the successful completion of its acquisition of the biopharmaceutical company, AkaRx, Inc.
NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced results from its first Phase 1/2 study evaluating the safety and efficacy of NplateÂ® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).
THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for NplateÂ® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP).
THOUSAND OAKS, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for NplateÂ® (romiplostim), at a Nov. 18 ceremony in London.
NEW YORK, Oct. 1 /PRNewswire-USNewswire/ -- The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition.
LACHEN, SWITZERLAND and HOBOKEN, N.J., Sept. 23 /PRNewswire/ -- Octapharma AG recently submitted its Biological License Application for octagam(R) 10% (human normal intravenous immunoglobulin, liquid) to the U.S.
BERLIN, June 7 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP).
- A volcanic mudflow.